Dr. Michael J. Palumbo, M.D.

Medicare patients and services

Medicare patients, 2024

273

Services billed

3,651

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 25 companies reported 325 payments worth $158,263 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 20 industry-funded studies in 2025, from 10 companies. The companies reported $1,313,109 in research payments for these studies, mostly to the institutions running them.

• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
  Eli Lilly and Company · Active, not recruiting · NCT06339008
• A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
  Novartis Pharmaceuticals Corporation
• A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
  Novartis Pharmaceuticals Corporation
• A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
  AstraZeneca UK Limited
• A multicentre, randomized, double-blind, placebo-controlled, dose find
  GlaxoSmithKline, LLC.
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
  Genzyme Corporation · Active, not recruiting · NCT05097287
• A randomized, double-blind, parallel group, multi-center study to eval
  GlaxoSmithKline, LLC.
• A 52-week, randomised, double-blind, double-dummy, parallel group, mul
  GlaxoSmithKline, LLC.
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urtic…
  Novartis Pharmaceuticals Corporation
• A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
  GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Allergy & Immunology clinicians in Pittsburgh

• James N. Deangelo, D.O.
• Richard L. Green, M.D.
• Ronald A. Landay, M.D.
• Allyson S. Larkin, MD
• David L. Miller, M.D.
• Andrew G. Vayonis, M.D.